Your cart is currently empty!
Ophthalmic Drugs Market Report 2025-2035
The global Ophthalmic Drugs market is projected to grow at a CAGR of 7.2% by 2035
Description
Visiongain’s most recent Ophthalmic Drugs Market Report 2025-2035 , gives a deep analysis of factors driving robust growth. Rising incidences of eye-related conditions-such as glaucoma, macular degeneration, diabetic retinopathy, and dry eye syndrome-are influencing the demand for advanced pharmaceutical solutions. This trend is further supported by an aging global population and lifestyle changes that increase susceptibility to these conditions, underscoring the need for innovative drug options. A strong pipeline of new ophthalmic drugs is also bolstering market expansion, as pharmaceutical companies invest substantially in R&D to introduce enhanced and novel treatments. These active developments are set to deliver more targeted and precise therapies, improving treatment options and accelerating market momentum. With sustained innovation and continuous advancements, the global ophthalmic drugs market is expected to maintain its growth trajectory in the coming years.
Side Effects of Drugs Likely to Challenge Industry Growth
Topical ophthalmic drugs can cause a variety of side effects, including temporary vision cloudiness, allergic reactions, visual disturbances, and stinging, burning, or itching. Less common but more severe side effects include sudden vision changes, intense headaches, tunnel vision, eye discomfort, pain behind the eyes, and signs of an eye infection, such as swelling and discharge. As a result, adverse effects, particularly those associated with topical steroidal drugs, may limit market growth.
Addressing drug-related side effects in the ophthalmic drugs market, particularly in developing countries, necessitates a comprehensive strategy. This includes increasing healthcare accessibility, developing medical infrastructure, educating patients, reducing counterfeit drug circulation, and enacting stringent regulatory frameworks to ensure the safety and efficacy of ophthalmic treatments. Apellis Pharmaceuticals’ drug pegcetacoplan, which was approved by the FDA for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), has raised safety concerns due to instances of intraocular inflammation (IOI), according to the American Society of Retina Specialists (ASRS). As of April 2023, the ASRS Research and Safety in Therapeutics (ReST) Committee began tracking reports of IOI, some of which resulted in severe retinal vasculitis, occlusive retinal vasculopathy, or vision loss. On 16th January 2024, a retrospective analysis revealed 14 cases of retinal vasculitis among 13 patients following their first pegcetacoplan injection, with inflammation typically manifesting around 10.5 days after the injection. Notably, retinal veins were more affected than arteries, and 57% of impacted eyes had significant vision acuity (VA) loss, with two cases necessitating enucleation due to severe complications. In addition, 43% of cases showed anterior segment neovascularisation. These findings highlight critical safety issues, emphasising the importance of continuous monitoring and real-world safety analysis of pegcetacoplan in order to better assess and manage associated risks.
Need industry data? Please contact us today.
What Questions Should You Ask before Buying a Market Research Report?
- How is the ophthalmic drugs market evolving?
- What is driving and restraining the ophthalmic drugs market?
- How will each ophthalmic drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
- How will the market shares for each ophthalmic drugs submarket develop from 2025 to 2035?
- What will be the main driver for the overall market from 2025 to 2035?
- Will leading ophthalmic drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
- Who are the leading players and what are their prospects over the forecast period?
- How will the industry evolve during the period between 2025 and 2035? What are the implications of ophthalmic drugs projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the ophthalmic drugs market?
- Where is the ophthalmic drugs market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Ophthalmic Drugs Market today, and over the next 10 years:
- Our 344-page report provides 129 tables, 178 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them – NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2035 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising ophthalmic drugs prices and recent developments.
Segments Covered in the Report
Type
- Prescription Drugs
- OTC Drugs
Indication
- Retinal Disorders
- Infection/Inflammation/Allergy
- Glaucoma
- Dry Eye
- Others
Route of Administration
- Topical
- Parenteral
Distribution Channel
- Hospital Pharmacies
- Drug Stores
- Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 26 leading national markets:
North America
- U.S.
- Canada
Europe
- Germany
- Spain
- UK
- France
- Italy
- Netherlands
- Switzerland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Malaysia
- Singapore
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Mexico
- Chile
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
Do you have any custom requirements we can help you with? Please contact us today.
The report also includes profiles and for some of the leading companies in the Ophthalmic Drugs Market 2025 to 2035, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
- AbbVie Inc.
- Alcon
- Alimera Sciences
- Apellis Pharmaceuticals
- Bausch + Lomb Corporation
- Bayer AG
- Breye Therapeutics ApS
- EyeBio
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services, Inc.
- Nicox
- Novaliq GmbH
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Santen Pharmaceutical Co., Ltd.
- SpliceBio
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
Overall world revenue for ophthalmic drugs market, 2025 to 2035 in terms of value the market will surpass US$35.0 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Ophthalmic Drugs Market, 2025 to 2035 report help you?
In summary, our 340+ page report provides you with the following knowledge:
- Revenue forecasts to 2035 for Ophthalmic Drugs Market, 2025 to 2035 Market, with forecasts for type, distribution channel, indication, route of administration, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2035 for five regional and 26 key national markets – See forecasts for the Ophthalmic Drugs Market, 2025 to 2035 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market – including company profiles for 21 of the major companies involved in the Ophthalmic Drugs Market, 2025 to 2035.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Ophthalmic Drugs Market, 2025 to 2035, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Ophthalmic Drugs Market Report 2025-2035: Forecasts by Type (Prescription Drugs, OTC Drugs), by Indication (Retinal Disorders, Infection/Inflammation/Allergy, Glaucoma, Dry Eye, Others), by Route of Administration (Topical, Parenteral), by Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Ophthalmic Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Rising Frequency and Occurrence of Eye-related Conditions
3.2.1.2 Technological Advancements and Innovations
3.2.1.3 Increasing Prevalence of Diabetes
3.2.1.4 Presence of Strong Emerging Pipeline Drugs
3.2.2 Market Restraining Factors
3.2.2.1 Lack of Health Insurance in the Developing Countries
3.2.2.2 Lack of Awareness Regarding the Available Treatment Options
3.2.2.3 Side Effects of Drugs
3.2.2.4 Patent Expiry of Blockbuster Drugs
3.2.2.5 Impact of Elevated R&D Expenses and Patent Loss on Popular Pharmaceuticals
3.2.2.6 Intensifying Competition in the Crowded Ophthalmic Drugs Market
3.2.3 Market Opportunities
3.2.3.1 Rise in Investment in Research and Development
3.2.3.2 Rise in Geriatric Population
3.2.3.3 Emergence of Digital Health Solutions and Telemedicine
3.2.3.4 Growing Regulatory Support for Innovation in the Ophthalmic Sector
3.2.3.5 E-Commerce and Online Pharmacies Unlock New Market Opportunities
3.3 Emerging Trends
3.4 Porterโs Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat of Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political
3.5.2 Economical
3.5.3 Social
3.5.4 Technological
3.6 Recent Approvals
4 Ophthalmic Drugs Market Analysis by Type
4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Ophthalmic Drugs Market Size Estimation and Forecast by Type
4.4 Prescription Drugs
4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.2 Market Share by Region, 2025 & 2035 (%)
4.5 OTC Drugs
4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
4.5.2 Market Share by Region, 2025 & 2035 (%)
5 Ophthalmic Drugs Market Analysis by Distribution Channel
5.1 Key Findings
5.2 Distribution Channel Segment: Market Attractiveness Index
5.4 Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
5.5 Hospital Pharmacies
5.5.1 Market Size by Region, 2025-2035 (US$ Billion)
5.5.2 Market Share by Region, 2025 & 2035 (%)
5.6 Drug Stores
5.6.1 Market Size by Region, 2025-2035 (US$ Billion)
5.6.2 Market Share by Region, 2025 & 2035 (%)
5.7 Online Pharmacies
5.7.1 Market Size by Region, 2025-2035 (US$ Billion)
5.7.2 Market Share by Region, 2025 & 2035 (%)
6 Ophthalmic Drugs Market Analysis by Indication
6.1 Key Findings
6.2 Indication Segment: Market Attractiveness Index
6.3 Ophthalmic Drugs Market Size Estimation and Forecast by Indications
6.4 Retinal Disorders
6.4.1 Market Size by Region, 2025-2035 (US$ Billion)
6.4.2 Market Share by Region, 2025 & 2035 (%)
6.5 Infection/Inflammation/Allergy
6.5.1 Market Size by Region, 2025-2035 (US$ Billion)
6.5.2 Market Share by Region, 2025 & 2035 (%)
6.6 Dry Eye
6.6.1 Market Size by Region, 2025-2035 (US$ Billion)
6.6.2 Market Share by Region, 2025 & 2035 (%)
6.7 Glaucoma
6.7.1 Market Size by Region, 2025-2035 (US$ Billion)
6.7.2 Market Share by Region, 2025 & 2035 (%)
6.8 Others
6.8.1 Market Size by Region, 2025-2035 (US$ Billion)
6.8.2 Market Share by Region, 2025 & 2035 (%)
7 Ophthalmic Drugs Market Analysis by Route of Administration
7.1 Key Findings
7.2 Route of Administration Segment: Market Attractiveness Index
7.4 Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
7.5 Topical
7.5.1 Market Size by Region, 2025-2035 (US$ Billion)
7.5.2 Market Share by Region, 2025 & 2035 (%)
7.6 Parenteral
7.6.1 Market Size by Region, 2025-2035 (US$ Billion)
7.6.2 Market Share by Region, 2025 & 2035 (%)
8 Ophthalmic Drugs Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 North America Ophthalmic Drugs Market Analysis
9.1 Key Findings
9.2 North America Ophthalmic Drugs Market Attractiveness Index
9.3 North America Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
9.4 North America Ophthalmic Drugs Market Size Estimation and Forecast by Country
9.5 North America Ophthalmic Drugs Market Size Estimation and Forecast by Type
9.6 North America Ophthalmic Drugs Market Size Estimation and Forecast by Distribution channel
9.7 North America Ophthalmic Drugs Market Size Estimation and Forecast by Indications
9.8 North America Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
9.9 U.S. Ophthalmic Drugs Market Analysis
9.10 Canada Ophthalmic Drugs Market Analysis
10 Europe Ophthalmic Drugs Market Analysis
10.1 Key Findings
10.2 Europe Ophthalmic Drugs Market Attractiveness Index
10.3 Europe Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
10.5 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Country
10.6 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Type
10.7 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
10.8 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Indications
10.9 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
10.10 Germany Ophthalmic Drugs Market Analysis
10.11 France Ophthalmic Drugs Market Analysis
10.12 UK Ophthalmic Drugs Market Analysis
10.13 Italy Ophthalmic Drugs Market Analysis
10.14 Spain Ophthalmic Drugs Market Analysis
10.15 Netherlands Ophthalmic Drugs Market Analysis
10.16 Switzerland Ophthalmic Drugs Market Analysis
10.17 Rest of Europe Ophthalmic Drugs Market Analysis
11 Asia Pacific Ophthalmic Drugs Market Analysis
11.1 Key Findings
11.2 Asia Pacific Ophthalmic Drugs Market Attractiveness Index
11.3 Asia Pacific Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
11.4 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Country
11.5 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Type
11.6 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
11.7 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Indications
11.9 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
11.10 Japan Ophthalmic Drugs Market Analysis
11.11 China Ophthalmic Drugs Market Analysis
11.12 India Ophthalmic Drugs Market Analysis
11.13 Australia Ophthalmic Drugs Market Analysis
11.14 South Korea Ophthalmic Drugs Market Analysis
11.15 Malaysia Ophthalmic Drugs Market Analysis
11.16 Singapore Ophthalmic Drugs Market Analysis
11.17 Rest of Asia Pacific Ophthalmic Drugs Market Analysis
12 Latin America Ophthalmic Drugs Market Analysis
12.1 Key Findings
12.2 Latin America Ophthalmic Drugs Market Attractiveness Index
12.3 Latin America Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
12.4 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Country
12.5 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Type
12.6 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
12.7 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Indications
12.8 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
12.9 Brazil Ophthalmic Drugs Market Analysis
12.10 Argentina Ophthalmic Drugs Market Analysis
12.11 Mexico Ophthalmic Drugs Market Analysis
12.12 Chile Ophthalmic Drugs Market Analysis
12.13 Rest of Latin America Ophthalmic Drugs Market Analysis
13 MEA Ophthalmic Drugs Market Analysis
13.1 Key Findings
13.2 MEA Ophthalmic Drugs Market Attractiveness Index
13.3 MEA Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
13.5 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Country
13.6 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Type
13.7 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
13.8 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Indications
13.9 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
13.10 GCC Ophthalmic Drugs Market Analysis
13.11 South Africa Ophthalmic Drugs Market Analysis
13.12 Rest of MEA Ophthalmic Drugs Market Analysis
14 Company Profiles
14.1 Strategic Outlook
14.2 Novartis AG
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Financial Analysis
14.2.3.1 Net Revenue, 2018-2023
14.2.3.2 Regional Market Shares, 2023
14.2.3.3 R&D Expense, 2018-2023
14.2.4 Product Benchmarking
14.2.5 Strategic Outlook
14.3 Bayer AG
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2018-2023
14.3.3.2 Regional Market Shares, 2023
14.3.3.3 Business Segment Market Shares, 2023
14.3.3.4 R&D Expense, 2018-2023
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Pfizer Inc.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Revenue, 2018-2023
14.4.3.2 Regional Market Shares, 2023
14.4.3.3 Business Segment Market Shares, 2023
14.4.3.4 R&D Expense, 2018-2023
14.4.4 Product Benchmarking
14.5 Bausch + Lomb Corporation
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Revenue, 2020-2023
14.5.3.2 R&D Expense, 2020-2023
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 Santen Pharmaceutical Co., Ltd.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Revenue, 2018-2023
14.6.3.2 Regional Market Shares, 2023
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Johnson & Johnson Services, Inc.
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Revenue, 2018-2023
14.7.3.2 Regional Market Shares, 2023
14.7.3.3 Business Segment Market Shares, 2023
14.7.3.4 R&D Expense, 2018-2023
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.9 Regeneron Pharmaceuticals Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Revenue, 2018-2023
14.9.3.2 R&D Expense, 2018-2023
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 AbbVie Inc.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Revenue, 2018-2023
14.10.3.2 Regional Market Shares, 2023
14.10.3.3 Business Segment Market Shares, 2023
14.10.3.4 R&D Expense, 2018-2023
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook
14.11 F. Hoffmann-La Roche Ltd
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Revenue, 2018-2023
14.11.3.2 Business Segment Market Shares, 2023
14.11.3.3 R&D Expense, 2018-2023
14.11.4 Product Benchmarking
14.11.5 Strategic Outlook
14.12 Teva Pharmaceutical Industries Ltd.
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Revenue, 2018-2023
14.12.3.2 Regional Market Shares, 2023
14.12.3.3 R&D Expense, 2018-2023
14.12.4 Product Benchmarking
14.12.5 Strategic Outlook
14.13 Apellis Pharmaceuticals
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Revenue, 2020-2023
14.13.4 Product Benchmarking
14.13.5 Strategic Outlook
14.14 Novaliq GmbH
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Product Benchmarking
14.14.4 Strategic Outlook
14.15 Alimera Sciences
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Revenue, 2018-2023
14.15.3.2 R&D Expense, 2018-2023
14.15.3.3 Regional Market Shares, 2023
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 EyeBio
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Product Benchmarking
14.16.4 Strategic Outlook
14.17 SpliceBio
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Product Benchmarking
14.17.4 Strategic Outlook
14.18 Breye Therapeutics ApS
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Product Benchmarking
14.18.4 Strategic Outlook
14.19 Nicox
14.19.1 Company Snapshot
14.19.2 Company Overview
14.19.3 Financial Analysis
14.19.3.1 Net Revenue, 2019-2023
14.19.5 Product Benchmarking
14.19.6 Strategic Outlook
14.20 Alcon
14.20.1 Company Snapshot
14.20.2 Company Overview
14.20.3 Financial Analysis
14.20.3.1 Net Revenue, 2018-2023
14.20.3.2 Business Segment Market Shares, 2023
14.20.3.3 Regional Market Shares, 2023
14.20.3.4 R&D Expense, 2018-2023
14.20.4 Product Benchmarking
14.20.5 Strategic Outlook
14.21 Viatris Inc.
14.21.1 Company Snapshot
14.21.2 Company Overview
14.21.3 Financial Analysis
14.21.3.1 Net Revenue, 2018-2023
14.21.3.2 Regional Market Shares, 2023
14.21.3.3 R&D Expense, 2018-2023
14.21.4 Product Benchmarking
14.21.5 Strategic Outlook
14.22 Sun Pharmaceutical Industries Ltd.
14.22.1 Company Snapshot
14.22.2 Company Overview
14.22.3 Financial Analysis
14.22.3.1 Net Revenue, 2018-2023
14.22.4 Product Benchmarking
15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players
List of Tables
Table 1 Ophthalmic Drugs Market Snapshot, 2025 & 2035 (US$ billion, CAGR %)
Table 2 Ophthalmic Drugs Market: Product Pipeline
Table 3 Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 4 Prescription Drugs Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 5 OTC Drugs Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 6 Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 7 Hospital Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 8 Drug Stores Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 9 Online Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 10 Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 11 Retinal Disorders Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 12 Infection/Inflammation/Allergy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 13 Dry Eye Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 14 Glaucoma Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 15 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 16 Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 17 Topical Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 18 Parenteral Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 19 Ophthalmic Drugs Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 20 North America Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 21 North America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 22 North America Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 23 North America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 24 North America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 25 U.S. Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 26 Canada Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 27 Europe Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 28 Europe Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 29 Europe Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 30 Europe Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 31 Europe Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 32 Germany Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 33 France Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 34 UK Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 35 Italy Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 36 Spain Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 37 Netherlands Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 38 Switzerland Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 39 Rest of Europe Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 40 Asia Pacific Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 41 Asia Pacific Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 42 Asia Pacific Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 43 Asia Pacific Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 44 Asia Pacific Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 45 Japan Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 46 China Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 47 India Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 48 Australia Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 49 South Korea Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 50 Malaysia Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 51 Singapore Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 52 Rest of Asia Pacific Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 53 Latin America Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 54 Latin America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 55 Latin America Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 56 Latin America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 57 Latin America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 58 Brazil Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 59 Argentina Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 60 Mexico Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 61 Chile Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 62 Rest of Latin America Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 63 MEA Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 64 MEA Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 65 MEA Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 66 MEA Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 67 MEA Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 68 GCC Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 69 South Africa Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 70 Rest of MEA Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 71 Strategic Outlook
Table 72 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 Novartis AG: Product Benchmarking
Table 74 Novartis AG: Strategic Outlook
Table 75 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 Bayer AG: Product Benchmarking
Table 77 Bayer AG: Strategic Outlook
Table 78 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Pfizer Inc.: Product Benchmarking
Table 80 Bausch + Lomb Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Bausch + Lomb Corporation: Product Benchmarking
Table 82 Bausch + Lomb Corporation: Strategic Outlook
Table 83 Santen Pharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Santen Pharmaceutical Co., Ltd.: Product Benchmarking
Table 85 Santen Pharmaceutical Co., Ltd.: Strategic Outlook
Table 86 Johnson & Johnson Services Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Johnson & Johnson Private Limited: Product Benchmarking
Table 88 Johnson & Johnson Private Limited: Strategic Outlook
Table 89 Regeneron Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Regeneron Pharmaceuticals Inc.: Product Benchmarking
Table 91 Regeneron Pharmaceuticals Inc.: Strategic Outlook
Table 92 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 AbbVie Inc.: Product Benchmarking
Table 94 AbbVie Inc.: Strategic Outlook
Table 95 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 97 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 98 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 100 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
Table 101 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Apellis Pharmaceuticals: Product Benchmarking
Table 103 Apellis Pharmaceuticals: Strategic Outlook
Table 104 Novaliq GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Novaliq GmbH.: Product Benchmarking
Table 106 Novaliq GmbH: Strategic Outlook
Table 107 Alimera Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Alimera Sciences: Product Benchmarking
Table 109 Alimera Sciences: Strategic Outlook
Table 110 EyeBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 EyeBio: Product Benchmarking
Table 112 EyeBio: Strategic Outlook
Table 113 SpliceBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 114 SpliceBio: Product Benchmarking
Table 115 SpliceBio: Strategic Outlook
Table 116 Breye Therapeutics ApS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 117 Breye Therapeutics ApS: Product Benchmarking
Table 118 Breye Therapeutics ApS: Strategic Outlook
Table 119 Nicox: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 Nicox: Product Benchmarking
Table 121 Nicox: Strategic Outlook
Table 122 Alcon: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Alcon: Product Benchmarking
Table 124 Alcon: Strategic Outlook
Table 125 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Viatris Inc.: Product Benchmarking
Table 127 Viatris Inc.: Strategic Outlook
Table 128 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 129 Sun Pharmaceutical Industries Ltd.: Product Benchmarking
List of Figures
Figure 1 Ophthalmic Drugs Market Segmentation
Figure 2 Ophthalmic Drugs Market by Type: Market Attractiveness Index
Figure 3 Ophthalmic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 4 Ophthalmic Drugs Market Forecast by Indications: Market Attractiveness Index
Figure 5 Ophthalmic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
Figure 6 Ophthalmic Drugs Market Attractiveness Index by Region
Figure 7 Ophthalmic Drugs Market: Market Dynamics
Figure 8 Ophthalmic Drugs Market: Porterโs Five Forces Analysis
Figure 9 Ophthalmic Drugs Market: PEST Analysis
Figure 10 Ophthalmic Drugs Market Forecast by Type: Market Attractiveness Index
Figure 11 Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 12 Ophthalmic Drugs Market Share Forecast by Type, 2025, 2030, 2035 (%)
Figure 13 Prescription Drugs Market Forecast by Region, 2025-2035 (US$ Billion)
Figure 14 Prescription Drugs Market Share Forecast by Region, 2025 & 2035 (%)
Figure 15 OTC Drugs Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 16 OTC Drugs Market Share Forecast by Region, 2025 & 2035 (%)
Figure 17 Ophthalmic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 18 Ophthalmic Drugs Market Forecast By Distribution Channel, 2025-2035 (US$ Billion, AGR %)
Figure 19 Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025, 2030, 2035 (%)
Figure 20 Hospital Pharmacies Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 21 Hospital Pharmacies Market Share Forecast by Region, 2025 & 2035 (%)
Figure 22 Drug Stores Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 23 Drug Stores Market Share Forecast by Region, 2025 & 2035 (%)
Figure 24 Online Pharmacies Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 25 Online Pharmacies Market Share Forecast by Region, 2025 & 2035 (%)
Figure 26 Ophthalmic Drugs Market Forecast by Indication: Market Attractiveness Index
Figure 27 Ophthalmic Drugs Market Forecast By Indications, 2025-2035 (US$ Billion, AGR %)
Figure 28 Ophthalmic Drugs Market Share Forecast by Indications, 2025, 2030, 2035 (%)
Figure 29 Retinal Disorders Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 30 Retinal Disorders Market Share Forecast by Region, 2025 & 2035 (%)
Figure 31 Infection/Inflammation/Allergy Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 32 Infection/Inflammation/Allergy Market Share Forecast by Region, 2025 & 2035 (%)
Figure 33 Dry Eye Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 34 Dry Eye Market Share Forecast by Region, 2025 & 2035 (%)
Figure 35 Glaucoma Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 36 Glaucoma Market Share Forecast by Region, 2025 & 2035 (%)
Figure 37 Others Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 38 Others Market Share Forecast by Region, 2025 & 2035 (%)
Figure 39 Ophthalmic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
Figure 40 Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
Figure 41 Ophthalmic Drugs Market Share Forecast by Route of administration, 2025, 2030, 2035 (%)
Figure 42 Topical Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 43 Topical Market Share Forecast by Region, 2025 & 2035 (%)
Figure 44 Parenteral Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 45 Parenteral Market Share Forecast by Region, 2025 & 2035 (%)
Figure 46 Ophthalmic Drugs Market Forecast by Region 2025 & 2035 (Revenue, CAGR%)
Figure 47 Ophthalmic Drugs Market Share Forecast by Region 2025, 2030, 2035 (%)
Figure 48 Ophthalmic Drugs Market by Region, 2025-2035 (US$ Billion, AGR (%), CAGR (%))
Figure 49 North America Ophthalmic Drugs Market Attractiveness Index
Figure 50 North America Ophthalmic Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 51 North America Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 52 North America Ophthalmic Drugs Market Share Forecast by Country, 2025 & 2035 (%)
Figure 53 North America Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 54 North America Ophthalmic Drugs Market Share Forecast by Type, 2025 & 2035 (%)
Figure 55 North America Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion
Figure 56 North America Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 57 North America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR %)
Figure 58 North America Ophthalmic Drugs Market Share Forecast by Indications, 2025 & 2035 (%)
Figure 59 North America Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
Figure 60 North America Ophthalmic Drugs Market Share Forecast by Route of Administration, 2025 & 2035 (%)
Figure 61 U.S. Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 62 Canada Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 63 Europe Ophthalmic Drugs Market Attractiveness Index
Figure 64 Europe Ophthalmic Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 65 Europe Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 66 Europe Ophthalmic Drugs Market Share Forecast by Country, 2025 & 2035 (%)
Figure 67 Europe Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 68 Europe Ophthalmic Drugs Market Share Forecast by Type, 2025 & 2035 (%)
Figure 69 Europe Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion
Figure 70 Europe Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 71 Europe Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR %)
Figure 72 Europe Ophthalmic Drugs Market Share Forecast by Indications, 2025 & 2035 (%)
Figure 73 Europe Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
Figure 74 Europe Ophthalmic Drugs Market Share Forecast by Route of Administration, 2025 & 2035 (%)
Figure 75 Germany Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 76 France Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 77 UK Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 78 Italy Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 79 Spain Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 80 Netherlands Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 81 Switzerland Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 82 Rest of Europe Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 83 Asia Pacific Ophthalmic Drugs Market Attractiveness Index
Figure 84 Asia Pacific Ophthalmic Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 85 Asia Pacific Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 86 Asia Pacific Ophthalmic Drugs Market Share Forecast by Country, 2025 & 2035 (%)
Figure 87 Asia Pacific Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 88 Asia Pacific Ophthalmic Drugs Market Share Forecast by Type, 2025 & 2035 (%)
Figure 89 Asia Pacific Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion
Figure 90 Asia Pacific Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 91 Asia Pacific Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR %)
Figure 92 Asia Pacific Ophthalmic Drugs Market Share Forecast by Indications, 2025 & 2035 (%)
Figure 93 Asia Pacific Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
Figure 94 Asia Pacific Ophthalmic Drugs Market Share Forecast by Route of Administration, 2025 & 2035 (%)
Figure 95 Japan Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 96 China Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 97 India Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 98 Australia Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 99 South Korea Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 100 Malaysia Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 101 Singapore Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 102 Rest of Asia Pacific Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 103 Latin America Ophthalmic Drugs Market Attractiveness Index
Figure 104 Latin America Ophthalmic Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 105 Latin America Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 106 Latin America Ophthalmic Drugs Market Share Forecast by Country, 2025 & 2035 (%)
Figure 107 Latin America Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 108 Latin America Ophthalmic Drugs Market Share Forecast by Type, 2025 & 2035 (%)
Figure 109 Latin America Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR %)
Figure 110 Latin America Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 111 Latin America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR %)
Figure 112 Latin America Ophthalmic Drugs Market Share Forecast by Indications, 2025 & 2035 (%)
Figure 113 Latin America Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
Figure 114 Latin America Ophthalmic Drugs Market Share Forecast by Route of Administration, 2025 & 2035 (%
Figure 115 Brazil Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 116 Argentina Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 117 Mexico Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 118 Chile Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 119 Rest of Latin America Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 120 MEA Ophthalmic Drugs Market Attractiveness Index
Figure 121 MEA Ophthalmic Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 122 MEA Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 123 MEA Ophthalmic Drugs Market Share Forecast by Country, 2025 & 2035 (%)
Figure 124 MEA Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 125 MEA Ophthalmic Drugs Market Share Forecast by Type, 2025 & 2035 (%)
Figure 126 MEA Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR %)
Figure 127 MEA Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 128 MEA Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR %)
Figure 129 MEA Ophthalmic Drugs Market Share Forecast by Indications, 2025 & 2035 (%)
Figure 130 MEA Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
Figure 131 MEA Ophthalmic Drugs Market Share Forecast by Route of Administration, 2025 & 2035 (%
Figure 132 GCC Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 133 South Africa Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 134 Rest of MEA Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 135 Novartis AG: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 136 Novartis AG: Regional Market Shares (%), 2023
Figure 137 Novartis AG: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 138 Bayer AG: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 139 Bayer AG: Regional Market Shares (%), 2023
Figure 140 Bayer AG: Business Segment Market Shares (%), 2023
Figure 141 Bayer AG: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 142 Pfizer Inc.: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 143 Pfizer Inc.: Regional Market Shares (%), 2023
Figure 144 Pfizer Inc.: Business Segment Market Shares (%), 2023
Figure 145 Pfizer Inc.: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 146 Bausch + Lomb Corporation: Annual Revenue, 2020-2023 (US$ Million, AGR %)
Figure 147 Bausch + Lomb Corporation: R&D Expense, 2020-2023 (US$ Million, AGR %)
Figure 148 Santen Pharmaceutical Co., Ltd.: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 149 Santen Pharmaceutical Co., Ltd.: Regional Market Shares (%), 2023
Figure 150 Johnson & Johnson Services, Inc.: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 151 Johnson & Johnson Services, Inc.: Regional Market Shares (%), 2023
Figure 152 Johnson & Johnson Services, Inc.: Business Segment Market Shares (%), 2023
Figure 153 Johnson & Johnson Private Limited: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 154 Regeneron Pharmaceuticals Inc.: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 155 Regeneron Pharmaceuticals Inc: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 156 AbbVie Inc.: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 157 AbbVie: Regional Market Shares (%), 2023
Figure 158 AbbVie: Business Segment Market Shares (%), 2023
Figure 159 AbbVie Inc.: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 160 F. Hoffmann-La Roche Ltd: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 161 F. Hoffmann-La Roche Ltd.: Business Segment Market Shares (%), 2023
Figure 162 F. Hoffmann-La Roche Ltd: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 163 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2018-2023 (US$ Million, AGR%)
Figure 164 Teva Pharmaceutical Industries Ltd.: Regional Market Shares (%), 2023
Figure 165 Teva Pharmaceutical Industries Ltd.: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 166 Apellis Pharmaceuticals: Annual Revenue, 2020-2023 (US$ Million, AGR %)
Figure 167 Alimera Sciences: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 168 Alimera Sciences: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 169 Alimera Sciences: Regional Market Shares, 2023 (%)
Figure 170 Nicox: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 171 Alcon: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 172 Alcon: Business Segment Market Shares (%), 2023
Figure 173 Alcon: Regional Market Shares (%), 2023
Figure 174 Alcon: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 175 Viatris Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 176 Viatris Inc.: Regional Market Shares (%), 2023
Figure 177 Viatris Inc.: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 178 Sun Pharmaceutical Industries Ltd.: Net Revenue, 2018-2023 (US$ Million, AGR %)
1.1 Objectives of the Study
1.2 Introduction to Ophthalmic Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Rising Frequency and Occurrence of Eye-related Conditions
3.2.1.2 Technological Advancements and Innovations
3.2.1.3 Increasing Prevalence of Diabetes
3.2.1.4 Presence of Strong Emerging Pipeline Drugs
3.2.2 Market Restraining Factors
3.2.2.1 Lack of Health Insurance in the Developing Countries
3.2.2.2 Lack of Awareness Regarding the Available Treatment Options
3.2.2.3 Side Effects of Drugs
3.2.2.4 Patent Expiry of Blockbuster Drugs
3.2.2.5 Impact of Elevated R&D Expenses and Patent Loss on Popular Pharmaceuticals
3.2.2.6 Intensifying Competition in the Crowded Ophthalmic Drugs Market
3.2.3 Market Opportunities
3.2.3.1 Rise in Investment in Research and Development
3.2.3.2 Rise in Geriatric Population
3.2.3.3 Emergence of Digital Health Solutions and Telemedicine
3.2.3.4 Growing Regulatory Support for Innovation in the Ophthalmic Sector
3.2.3.5 E-Commerce and Online Pharmacies Unlock New Market Opportunities
3.3 Emerging Trends
3.4 Porterโs Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat of Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political
3.5.2 Economical
3.5.3 Social
3.5.4 Technological
3.6 Recent Approvals
4 Ophthalmic Drugs Market Analysis by Type
4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Ophthalmic Drugs Market Size Estimation and Forecast by Type
4.4 Prescription Drugs
4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
4.4.2 Market Share by Region, 2025 & 2035 (%)
4.5 OTC Drugs
4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
4.5.2 Market Share by Region, 2025 & 2035 (%)
5 Ophthalmic Drugs Market Analysis by Distribution Channel
5.1 Key Findings
5.2 Distribution Channel Segment: Market Attractiveness Index
5.4 Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
5.5 Hospital Pharmacies
5.5.1 Market Size by Region, 2025-2035 (US$ Billion)
5.5.2 Market Share by Region, 2025 & 2035 (%)
5.6 Drug Stores
5.6.1 Market Size by Region, 2025-2035 (US$ Billion)
5.6.2 Market Share by Region, 2025 & 2035 (%)
5.7 Online Pharmacies
5.7.1 Market Size by Region, 2025-2035 (US$ Billion)
5.7.2 Market Share by Region, 2025 & 2035 (%)
6 Ophthalmic Drugs Market Analysis by Indication
6.1 Key Findings
6.2 Indication Segment: Market Attractiveness Index
6.3 Ophthalmic Drugs Market Size Estimation and Forecast by Indications
6.4 Retinal Disorders
6.4.1 Market Size by Region, 2025-2035 (US$ Billion)
6.4.2 Market Share by Region, 2025 & 2035 (%)
6.5 Infection/Inflammation/Allergy
6.5.1 Market Size by Region, 2025-2035 (US$ Billion)
6.5.2 Market Share by Region, 2025 & 2035 (%)
6.6 Dry Eye
6.6.1 Market Size by Region, 2025-2035 (US$ Billion)
6.6.2 Market Share by Region, 2025 & 2035 (%)
6.7 Glaucoma
6.7.1 Market Size by Region, 2025-2035 (US$ Billion)
6.7.2 Market Share by Region, 2025 & 2035 (%)
6.8 Others
6.8.1 Market Size by Region, 2025-2035 (US$ Billion)
6.8.2 Market Share by Region, 2025 & 2035 (%)
7 Ophthalmic Drugs Market Analysis by Route of Administration
7.1 Key Findings
7.2 Route of Administration Segment: Market Attractiveness Index
7.4 Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
7.5 Topical
7.5.1 Market Size by Region, 2025-2035 (US$ Billion)
7.5.2 Market Share by Region, 2025 & 2035 (%)
7.6 Parenteral
7.6.1 Market Size by Region, 2025-2035 (US$ Billion)
7.6.2 Market Share by Region, 2025 & 2035 (%)
8 Ophthalmic Drugs Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 North America Ophthalmic Drugs Market Analysis
9.1 Key Findings
9.2 North America Ophthalmic Drugs Market Attractiveness Index
9.3 North America Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
9.4 North America Ophthalmic Drugs Market Size Estimation and Forecast by Country
9.5 North America Ophthalmic Drugs Market Size Estimation and Forecast by Type
9.6 North America Ophthalmic Drugs Market Size Estimation and Forecast by Distribution channel
9.7 North America Ophthalmic Drugs Market Size Estimation and Forecast by Indications
9.8 North America Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
9.9 U.S. Ophthalmic Drugs Market Analysis
9.10 Canada Ophthalmic Drugs Market Analysis
10 Europe Ophthalmic Drugs Market Analysis
10.1 Key Findings
10.2 Europe Ophthalmic Drugs Market Attractiveness Index
10.3 Europe Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
10.5 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Country
10.6 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Type
10.7 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
10.8 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Indications
10.9 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
10.10 Germany Ophthalmic Drugs Market Analysis
10.11 France Ophthalmic Drugs Market Analysis
10.12 UK Ophthalmic Drugs Market Analysis
10.13 Italy Ophthalmic Drugs Market Analysis
10.14 Spain Ophthalmic Drugs Market Analysis
10.15 Netherlands Ophthalmic Drugs Market Analysis
10.16 Switzerland Ophthalmic Drugs Market Analysis
10.17 Rest of Europe Ophthalmic Drugs Market Analysis
11 Asia Pacific Ophthalmic Drugs Market Analysis
11.1 Key Findings
11.2 Asia Pacific Ophthalmic Drugs Market Attractiveness Index
11.3 Asia Pacific Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
11.4 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Country
11.5 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Type
11.6 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
11.7 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Indications
11.9 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
11.10 Japan Ophthalmic Drugs Market Analysis
11.11 China Ophthalmic Drugs Market Analysis
11.12 India Ophthalmic Drugs Market Analysis
11.13 Australia Ophthalmic Drugs Market Analysis
11.14 South Korea Ophthalmic Drugs Market Analysis
11.15 Malaysia Ophthalmic Drugs Market Analysis
11.16 Singapore Ophthalmic Drugs Market Analysis
11.17 Rest of Asia Pacific Ophthalmic Drugs Market Analysis
12 Latin America Ophthalmic Drugs Market Analysis
12.1 Key Findings
12.2 Latin America Ophthalmic Drugs Market Attractiveness Index
12.3 Latin America Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
12.4 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Country
12.5 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Type
12.6 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
12.7 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Indications
12.8 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
12.9 Brazil Ophthalmic Drugs Market Analysis
12.10 Argentina Ophthalmic Drugs Market Analysis
12.11 Mexico Ophthalmic Drugs Market Analysis
12.12 Chile Ophthalmic Drugs Market Analysis
12.13 Rest of Latin America Ophthalmic Drugs Market Analysis
13 MEA Ophthalmic Drugs Market Analysis
13.1 Key Findings
13.2 MEA Ophthalmic Drugs Market Attractiveness Index
13.3 MEA Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
13.5 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Country
13.6 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Type
13.7 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
13.8 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Indications
13.9 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
13.10 GCC Ophthalmic Drugs Market Analysis
13.11 South Africa Ophthalmic Drugs Market Analysis
13.12 Rest of MEA Ophthalmic Drugs Market Analysis
14 Company Profiles
14.1 Strategic Outlook
14.2 Novartis AG
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Financial Analysis
14.2.3.1 Net Revenue, 2018-2023
14.2.3.2 Regional Market Shares, 2023
14.2.3.3 R&D Expense, 2018-2023
14.2.4 Product Benchmarking
14.2.5 Strategic Outlook
14.3 Bayer AG
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2018-2023
14.3.3.2 Regional Market Shares, 2023
14.3.3.3 Business Segment Market Shares, 2023
14.3.3.4 R&D Expense, 2018-2023
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Pfizer Inc.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Revenue, 2018-2023
14.4.3.2 Regional Market Shares, 2023
14.4.3.3 Business Segment Market Shares, 2023
14.4.3.4 R&D Expense, 2018-2023
14.4.4 Product Benchmarking
14.5 Bausch + Lomb Corporation
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Revenue, 2020-2023
14.5.3.2 R&D Expense, 2020-2023
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 Santen Pharmaceutical Co., Ltd.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Revenue, 2018-2023
14.6.3.2 Regional Market Shares, 2023
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Johnson & Johnson Services, Inc.
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Revenue, 2018-2023
14.7.3.2 Regional Market Shares, 2023
14.7.3.3 Business Segment Market Shares, 2023
14.7.3.4 R&D Expense, 2018-2023
14.7.4 Product Benchmarking
14.7.5 Strategic Outlook
14.9 Regeneron Pharmaceuticals Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Revenue, 2018-2023
14.9.3.2 R&D Expense, 2018-2023
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 AbbVie Inc.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Revenue, 2018-2023
14.10.3.2 Regional Market Shares, 2023
14.10.3.3 Business Segment Market Shares, 2023
14.10.3.4 R&D Expense, 2018-2023
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook
14.11 F. Hoffmann-La Roche Ltd
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Revenue, 2018-2023
14.11.3.2 Business Segment Market Shares, 2023
14.11.3.3 R&D Expense, 2018-2023
14.11.4 Product Benchmarking
14.11.5 Strategic Outlook
14.12 Teva Pharmaceutical Industries Ltd.
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Revenue, 2018-2023
14.12.3.2 Regional Market Shares, 2023
14.12.3.3 R&D Expense, 2018-2023
14.12.4 Product Benchmarking
14.12.5 Strategic Outlook
14.13 Apellis Pharmaceuticals
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Revenue, 2020-2023
14.13.4 Product Benchmarking
14.13.5 Strategic Outlook
14.14 Novaliq GmbH
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Product Benchmarking
14.14.4 Strategic Outlook
14.15 Alimera Sciences
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Revenue, 2018-2023
14.15.3.2 R&D Expense, 2018-2023
14.15.3.3 Regional Market Shares, 2023
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 EyeBio
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Product Benchmarking
14.16.4 Strategic Outlook
14.17 SpliceBio
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Product Benchmarking
14.17.4 Strategic Outlook
14.18 Breye Therapeutics ApS
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Product Benchmarking
14.18.4 Strategic Outlook
14.19 Nicox
14.19.1 Company Snapshot
14.19.2 Company Overview
14.19.3 Financial Analysis
14.19.3.1 Net Revenue, 2019-2023
14.19.5 Product Benchmarking
14.19.6 Strategic Outlook
14.20 Alcon
14.20.1 Company Snapshot
14.20.2 Company Overview
14.20.3 Financial Analysis
14.20.3.1 Net Revenue, 2018-2023
14.20.3.2 Business Segment Market Shares, 2023
14.20.3.3 Regional Market Shares, 2023
14.20.3.4 R&D Expense, 2018-2023
14.20.4 Product Benchmarking
14.20.5 Strategic Outlook
14.21 Viatris Inc.
14.21.1 Company Snapshot
14.21.2 Company Overview
14.21.3 Financial Analysis
14.21.3.1 Net Revenue, 2018-2023
14.21.3.2 Regional Market Shares, 2023
14.21.3.3 R&D Expense, 2018-2023
14.21.4 Product Benchmarking
14.21.5 Strategic Outlook
14.22 Sun Pharmaceutical Industries Ltd.
14.22.1 Company Snapshot
14.22.2 Company Overview
14.22.3 Financial Analysis
14.22.3.1 Net Revenue, 2018-2023
14.22.4 Product Benchmarking
15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players
List of Tables
Table 1 Ophthalmic Drugs Market Snapshot, 2025 & 2035 (US$ billion, CAGR %)
Table 2 Ophthalmic Drugs Market: Product Pipeline
Table 3 Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 4 Prescription Drugs Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 5 OTC Drugs Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 6 Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 7 Hospital Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 8 Drug Stores Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 9 Online Pharmacies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 10 Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 11 Retinal Disorders Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 12 Infection/Inflammation/Allergy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 13 Dry Eye Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 14 Glaucoma Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 15 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 16 Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 17 Topical Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 18 Parenteral Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 19 Ophthalmic Drugs Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 20 North America Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 21 North America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 22 North America Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 23 North America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 24 North America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 25 U.S. Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 26 Canada Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 27 Europe Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 28 Europe Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 29 Europe Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 30 Europe Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 31 Europe Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 32 Germany Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 33 France Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 34 UK Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 35 Italy Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 36 Spain Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 37 Netherlands Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 38 Switzerland Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 39 Rest of Europe Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 40 Asia Pacific Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 41 Asia Pacific Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 42 Asia Pacific Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 43 Asia Pacific Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 44 Asia Pacific Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 45 Japan Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 46 China Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 47 India Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 48 Australia Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 49 South Korea Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 50 Malaysia Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 51 Singapore Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 52 Rest of Asia Pacific Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 53 Latin America Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 54 Latin America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 55 Latin America Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 56 Latin America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 57 Latin America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 58 Brazil Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 59 Argentina Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 60 Mexico Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 61 Chile Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 62 Rest of Latin America Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 63 MEA Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 64 MEA Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 65 MEA Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 66 MEA Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 67 MEA Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR%, CAGR%)
Table 68 GCC Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 69 South Africa Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 70 Rest of MEA Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %, CAGR %)
Table 71 Strategic Outlook
Table 72 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 Novartis AG: Product Benchmarking
Table 74 Novartis AG: Strategic Outlook
Table 75 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 Bayer AG: Product Benchmarking
Table 77 Bayer AG: Strategic Outlook
Table 78 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Pfizer Inc.: Product Benchmarking
Table 80 Bausch + Lomb Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Bausch + Lomb Corporation: Product Benchmarking
Table 82 Bausch + Lomb Corporation: Strategic Outlook
Table 83 Santen Pharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Santen Pharmaceutical Co., Ltd.: Product Benchmarking
Table 85 Santen Pharmaceutical Co., Ltd.: Strategic Outlook
Table 86 Johnson & Johnson Services Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Johnson & Johnson Private Limited: Product Benchmarking
Table 88 Johnson & Johnson Private Limited: Strategic Outlook
Table 89 Regeneron Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Regeneron Pharmaceuticals Inc.: Product Benchmarking
Table 91 Regeneron Pharmaceuticals Inc.: Strategic Outlook
Table 92 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 AbbVie Inc.: Product Benchmarking
Table 94 AbbVie Inc.: Strategic Outlook
Table 95 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 97 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 98 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 100 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
Table 101 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Apellis Pharmaceuticals: Product Benchmarking
Table 103 Apellis Pharmaceuticals: Strategic Outlook
Table 104 Novaliq GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Novaliq GmbH.: Product Benchmarking
Table 106 Novaliq GmbH: Strategic Outlook
Table 107 Alimera Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Alimera Sciences: Product Benchmarking
Table 109 Alimera Sciences: Strategic Outlook
Table 110 EyeBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 EyeBio: Product Benchmarking
Table 112 EyeBio: Strategic Outlook
Table 113 SpliceBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 114 SpliceBio: Product Benchmarking
Table 115 SpliceBio: Strategic Outlook
Table 116 Breye Therapeutics ApS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 117 Breye Therapeutics ApS: Product Benchmarking
Table 118 Breye Therapeutics ApS: Strategic Outlook
Table 119 Nicox: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 Nicox: Product Benchmarking
Table 121 Nicox: Strategic Outlook
Table 122 Alcon: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Alcon: Product Benchmarking
Table 124 Alcon: Strategic Outlook
Table 125 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Viatris Inc.: Product Benchmarking
Table 127 Viatris Inc.: Strategic Outlook
Table 128 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 129 Sun Pharmaceutical Industries Ltd.: Product Benchmarking
List of Figures
Figure 1 Ophthalmic Drugs Market Segmentation
Figure 2 Ophthalmic Drugs Market by Type: Market Attractiveness Index
Figure 3 Ophthalmic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 4 Ophthalmic Drugs Market Forecast by Indications: Market Attractiveness Index
Figure 5 Ophthalmic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
Figure 6 Ophthalmic Drugs Market Attractiveness Index by Region
Figure 7 Ophthalmic Drugs Market: Market Dynamics
Figure 8 Ophthalmic Drugs Market: Porterโs Five Forces Analysis
Figure 9 Ophthalmic Drugs Market: PEST Analysis
Figure 10 Ophthalmic Drugs Market Forecast by Type: Market Attractiveness Index
Figure 11 Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 12 Ophthalmic Drugs Market Share Forecast by Type, 2025, 2030, 2035 (%)
Figure 13 Prescription Drugs Market Forecast by Region, 2025-2035 (US$ Billion)
Figure 14 Prescription Drugs Market Share Forecast by Region, 2025 & 2035 (%)
Figure 15 OTC Drugs Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 16 OTC Drugs Market Share Forecast by Region, 2025 & 2035 (%)
Figure 17 Ophthalmic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 18 Ophthalmic Drugs Market Forecast By Distribution Channel, 2025-2035 (US$ Billion, AGR %)
Figure 19 Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025, 2030, 2035 (%)
Figure 20 Hospital Pharmacies Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 21 Hospital Pharmacies Market Share Forecast by Region, 2025 & 2035 (%)
Figure 22 Drug Stores Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 23 Drug Stores Market Share Forecast by Region, 2025 & 2035 (%)
Figure 24 Online Pharmacies Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 25 Online Pharmacies Market Share Forecast by Region, 2025 & 2035 (%)
Figure 26 Ophthalmic Drugs Market Forecast by Indication: Market Attractiveness Index
Figure 27 Ophthalmic Drugs Market Forecast By Indications, 2025-2035 (US$ Billion, AGR %)
Figure 28 Ophthalmic Drugs Market Share Forecast by Indications, 2025, 2030, 2035 (%)
Figure 29 Retinal Disorders Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 30 Retinal Disorders Market Share Forecast by Region, 2025 & 2035 (%)
Figure 31 Infection/Inflammation/Allergy Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 32 Infection/Inflammation/Allergy Market Share Forecast by Region, 2025 & 2035 (%)
Figure 33 Dry Eye Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 34 Dry Eye Market Share Forecast by Region, 2025 & 2035 (%)
Figure 35 Glaucoma Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 36 Glaucoma Market Share Forecast by Region, 2025 & 2035 (%)
Figure 37 Others Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 38 Others Market Share Forecast by Region, 2025 & 2035 (%)
Figure 39 Ophthalmic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
Figure 40 Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
Figure 41 Ophthalmic Drugs Market Share Forecast by Route of administration, 2025, 2030, 2035 (%)
Figure 42 Topical Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 43 Topical Market Share Forecast by Region, 2025 & 2035 (%)
Figure 44 Parenteral Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
Figure 45 Parenteral Market Share Forecast by Region, 2025 & 2035 (%)
Figure 46 Ophthalmic Drugs Market Forecast by Region 2025 & 2035 (Revenue, CAGR%)
Figure 47 Ophthalmic Drugs Market Share Forecast by Region 2025, 2030, 2035 (%)
Figure 48 Ophthalmic Drugs Market by Region, 2025-2035 (US$ Billion, AGR (%), CAGR (%))
Figure 49 North America Ophthalmic Drugs Market Attractiveness Index
Figure 50 North America Ophthalmic Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 51 North America Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 52 North America Ophthalmic Drugs Market Share Forecast by Country, 2025 & 2035 (%)
Figure 53 North America Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 54 North America Ophthalmic Drugs Market Share Forecast by Type, 2025 & 2035 (%)
Figure 55 North America Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion
Figure 56 North America Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 57 North America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR %)
Figure 58 North America Ophthalmic Drugs Market Share Forecast by Indications, 2025 & 2035 (%)
Figure 59 North America Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
Figure 60 North America Ophthalmic Drugs Market Share Forecast by Route of Administration, 2025 & 2035 (%)
Figure 61 U.S. Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 62 Canada Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 63 Europe Ophthalmic Drugs Market Attractiveness Index
Figure 64 Europe Ophthalmic Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 65 Europe Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 66 Europe Ophthalmic Drugs Market Share Forecast by Country, 2025 & 2035 (%)
Figure 67 Europe Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 68 Europe Ophthalmic Drugs Market Share Forecast by Type, 2025 & 2035 (%)
Figure 69 Europe Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion
Figure 70 Europe Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 71 Europe Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR %)
Figure 72 Europe Ophthalmic Drugs Market Share Forecast by Indications, 2025 & 2035 (%)
Figure 73 Europe Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
Figure 74 Europe Ophthalmic Drugs Market Share Forecast by Route of Administration, 2025 & 2035 (%)
Figure 75 Germany Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 76 France Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 77 UK Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 78 Italy Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 79 Spain Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 80 Netherlands Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 81 Switzerland Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 82 Rest of Europe Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 83 Asia Pacific Ophthalmic Drugs Market Attractiveness Index
Figure 84 Asia Pacific Ophthalmic Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 85 Asia Pacific Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 86 Asia Pacific Ophthalmic Drugs Market Share Forecast by Country, 2025 & 2035 (%)
Figure 87 Asia Pacific Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 88 Asia Pacific Ophthalmic Drugs Market Share Forecast by Type, 2025 & 2035 (%)
Figure 89 Asia Pacific Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion
Figure 90 Asia Pacific Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 91 Asia Pacific Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR %)
Figure 92 Asia Pacific Ophthalmic Drugs Market Share Forecast by Indications, 2025 & 2035 (%)
Figure 93 Asia Pacific Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
Figure 94 Asia Pacific Ophthalmic Drugs Market Share Forecast by Route of Administration, 2025 & 2035 (%)
Figure 95 Japan Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 96 China Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 97 India Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 98 Australia Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 99 South Korea Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 100 Malaysia Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 101 Singapore Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 102 Rest of Asia Pacific Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 103 Latin America Ophthalmic Drugs Market Attractiveness Index
Figure 104 Latin America Ophthalmic Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 105 Latin America Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 106 Latin America Ophthalmic Drugs Market Share Forecast by Country, 2025 & 2035 (%)
Figure 107 Latin America Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 108 Latin America Ophthalmic Drugs Market Share Forecast by Type, 2025 & 2035 (%)
Figure 109 Latin America Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR %)
Figure 110 Latin America Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 111 Latin America Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR %)
Figure 112 Latin America Ophthalmic Drugs Market Share Forecast by Indications, 2025 & 2035 (%)
Figure 113 Latin America Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
Figure 114 Latin America Ophthalmic Drugs Market Share Forecast by Route of Administration, 2025 & 2035 (%
Figure 115 Brazil Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 116 Argentina Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 117 Mexico Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 118 Chile Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 119 Rest of Latin America Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 120 MEA Ophthalmic Drugs Market Attractiveness Index
Figure 121 MEA Ophthalmic Drugs Market by Region, 2025, 2030 & 2035 (US$ Billion)
Figure 122 MEA Ophthalmic Drugs Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
Figure 123 MEA Ophthalmic Drugs Market Share Forecast by Country, 2025 & 2035 (%)
Figure 124 MEA Ophthalmic Drugs Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
Figure 125 MEA Ophthalmic Drugs Market Share Forecast by Type, 2025 & 2035 (%)
Figure 126 MEA Ophthalmic Drugs Market Forecast by Distribution Channel, 2025-2035 (US$ Billion, AGR %)
Figure 127 MEA Ophthalmic Drugs Market Share Forecast by Distribution Channel, 2025 & 2035 (%)
Figure 128 MEA Ophthalmic Drugs Market Forecast by Indications, 2025-2035 (US$ Billion, AGR %)
Figure 129 MEA Ophthalmic Drugs Market Share Forecast by Indications, 2025 & 2035 (%)
Figure 130 MEA Ophthalmic Drugs Market Forecast by Route of Administration, 2025-2035 (US$ Billion, AGR %)
Figure 131 MEA Ophthalmic Drugs Market Share Forecast by Route of Administration, 2025 & 2035 (%
Figure 132 GCC Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 133 South Africa Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 134 Rest of MEA Ophthalmic Drugs Market Forecast, 2025-2035 (US$ Billion, AGR %)
Figure 135 Novartis AG: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 136 Novartis AG: Regional Market Shares (%), 2023
Figure 137 Novartis AG: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 138 Bayer AG: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 139 Bayer AG: Regional Market Shares (%), 2023
Figure 140 Bayer AG: Business Segment Market Shares (%), 2023
Figure 141 Bayer AG: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 142 Pfizer Inc.: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 143 Pfizer Inc.: Regional Market Shares (%), 2023
Figure 144 Pfizer Inc.: Business Segment Market Shares (%), 2023
Figure 145 Pfizer Inc.: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 146 Bausch + Lomb Corporation: Annual Revenue, 2020-2023 (US$ Million, AGR %)
Figure 147 Bausch + Lomb Corporation: R&D Expense, 2020-2023 (US$ Million, AGR %)
Figure 148 Santen Pharmaceutical Co., Ltd.: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 149 Santen Pharmaceutical Co., Ltd.: Regional Market Shares (%), 2023
Figure 150 Johnson & Johnson Services, Inc.: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 151 Johnson & Johnson Services, Inc.: Regional Market Shares (%), 2023
Figure 152 Johnson & Johnson Services, Inc.: Business Segment Market Shares (%), 2023
Figure 153 Johnson & Johnson Private Limited: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 154 Regeneron Pharmaceuticals Inc.: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 155 Regeneron Pharmaceuticals Inc: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 156 AbbVie Inc.: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 157 AbbVie: Regional Market Shares (%), 2023
Figure 158 AbbVie: Business Segment Market Shares (%), 2023
Figure 159 AbbVie Inc.: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 160 F. Hoffmann-La Roche Ltd: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 161 F. Hoffmann-La Roche Ltd.: Business Segment Market Shares (%), 2023
Figure 162 F. Hoffmann-La Roche Ltd: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 163 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2018-2023 (US$ Million, AGR%)
Figure 164 Teva Pharmaceutical Industries Ltd.: Regional Market Shares (%), 2023
Figure 165 Teva Pharmaceutical Industries Ltd.: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 166 Apellis Pharmaceuticals: Annual Revenue, 2020-2023 (US$ Million, AGR %)
Figure 167 Alimera Sciences: Annual Revenue, 2018-2023 (US$ Million, AGR %)
Figure 168 Alimera Sciences: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 169 Alimera Sciences: Regional Market Shares, 2023 (%)
Figure 170 Nicox: Net Revenue, 2019-2023 (US$ Million, AGR %)
Figure 171 Alcon: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 172 Alcon: Business Segment Market Shares (%), 2023
Figure 173 Alcon: Regional Market Shares (%), 2023
Figure 174 Alcon: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 175 Viatris Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
Figure 176 Viatris Inc.: Regional Market Shares (%), 2023
Figure 177 Viatris Inc.: R&D Expense, 2018-2023 (US$ Million, AGR %)
Figure 178 Sun Pharmaceutical Industries Ltd.: Net Revenue, 2018-2023 (US$ Million, AGR %)
List of Companies Profiled in the Report
AbbVie Inc.
Alcon
Alimera Sciences
Apellis Pharmaceuticals
Bausch + Lomb Corporation
Bayer AG
Breye Therapeutics ApS
EyeBio
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc.
Nicox
Novaliq GmbH
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Santen Pharmaceutical Co., Ltd.
SpliceBio
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
List of Other Companies Mentioned in the Report
4D Molecular Therapeutics
AimMax Therapeutics
Alteogen
Amman Pharmaceuticals Industries
Atsena Therapeutics
Aurion Biotech
Bioeq AG
Caplin Steriles Limited
Capsida Biotherapeutics Inc.
Coherus BioSciences
Eyenovia, Inc.
Formosa Pharmaceuticals
Formycon AG
Glaukos Corporation
Glenmark Pharmaceuticals Ltd.
Golgi Neurosciences S.r.l.
Harrow
Huons Co. Ltd.
Kowa Company, Ltd.
Kwangdong Pharmaceutical Co., Ltd.
Luye Pharma Group
MS Pharma
Neurotech Pharmaceuticals, Inc.
Orasis Pharmaceuticals
Ocugen, Inc.
Ocular Therapeutix, Inc.
Oculis Holding AG
Ocumension Therapeutics
Opus Genetics
Ora, Inc.
Palatin Technologies, Inc.
Polpharma Biologics Group BV
REGENXBIO Inc.
RTW Investments, LP
Skyline Therapeutics
Trukera Medical
Viridian Therapeutics, Inc.
Zhaoke Ophthalmology Limited
List of Associations Mentioned in the Report
Centers for Disease Control and Prevention (CDC)
Drugs Controller General of India (DCGI)
European Medicines Agency (EMA)
Glaucoma Research Foundation (GRF)
Global Alliances and External Research (GAER)
Institute of Molecular and Clinical Ophthalmology Basel (IOB)
International Diabetes Federation (IDF)
Ministry of Health, Labour and Welfare (MHLW)
National Health Service (NHS)
National Medical Products Administration (NMPA)
Singapore Eye Research Institute (SERI)
U.S. Food and Drug Administration (FDA)
UCL Institute of Ophthalmology (IoO)
UK Medicines & Healthcare Regulatory Agency (MHRA)
World Health Organization (WHO)
AbbVie Inc.
Alcon
Alimera Sciences
Apellis Pharmaceuticals
Bausch + Lomb Corporation
Bayer AG
Breye Therapeutics ApS
EyeBio
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc.
Nicox
Novaliq GmbH
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Santen Pharmaceutical Co., Ltd.
SpliceBio
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
List of Other Companies Mentioned in the Report
4D Molecular Therapeutics
AimMax Therapeutics
Alteogen
Amman Pharmaceuticals Industries
Atsena Therapeutics
Aurion Biotech
Bioeq AG
Caplin Steriles Limited
Capsida Biotherapeutics Inc.
Coherus BioSciences
Eyenovia, Inc.
Formosa Pharmaceuticals
Formycon AG
Glaukos Corporation
Glenmark Pharmaceuticals Ltd.
Golgi Neurosciences S.r.l.
Harrow
Huons Co. Ltd.
Kowa Company, Ltd.
Kwangdong Pharmaceutical Co., Ltd.
Luye Pharma Group
MS Pharma
Neurotech Pharmaceuticals, Inc.
Orasis Pharmaceuticals
Ocugen, Inc.
Ocular Therapeutix, Inc.
Oculis Holding AG
Ocumension Therapeutics
Opus Genetics
Ora, Inc.
Palatin Technologies, Inc.
Polpharma Biologics Group BV
REGENXBIO Inc.
RTW Investments, LP
Skyline Therapeutics
Trukera Medical
Viridian Therapeutics, Inc.
Zhaoke Ophthalmology Limited
List of Associations Mentioned in the Report
Centers for Disease Control and Prevention (CDC)
Drugs Controller General of India (DCGI)
European Medicines Agency (EMA)
Glaucoma Research Foundation (GRF)
Global Alliances and External Research (GAER)
Institute of Molecular and Clinical Ophthalmology Basel (IOB)
International Diabetes Federation (IDF)
Ministry of Health, Labour and Welfare (MHLW)
National Health Service (NHS)
National Medical Products Administration (NMPA)
Singapore Eye Research Institute (SERI)
U.S. Food and Drug Administration (FDA)
UCL Institute of Ophthalmology (IoO)
UK Medicines & Healthcare Regulatory Agency (MHRA)
World Health Organization (WHO)
